Recital 5, Directive (EU) 2011/62

In forcecited 1×

A definition of ‘falsified medicinal product’ should be introduced in order to clearly distinguish falsified medicinal products from other illegal medicinal products, as well as from products infringing intellectual property rights. Furthermore, medicinal products with unintentional quality defects resulting from manufacturing or distribution errors should not be confused with falsified medicinal products. To ensure uniform application of this Directive, the terms ‘active substance’ and ‘excipient’ should also be defined.

  • Opinion of Advocate General Szpunar delivered on 13 January 2022. Novartis Pharma GmbH v Abacus Medicine A/S.Decision

    Likewise, the objectives of the fight against falsified medicinal products must be achieved by means of specific provisions adopted for that purpose and those provisions must be complied with throughout the supply chain. Trade mark …

    13 Jan 2022 · 62020CC0147